Allergic reactions prompt Moderna COVID vaccine pause in California
Backed by a $202 million fundraiser, biotech Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following a phase 3 trial success.
Mylan finalises rebate deal with US government.
UK biotech to focus on respiratory drugs after house dust mite therapy fails.
More trouble for embattled Mylan.
Recall follows two reports that allergy injection device failed.
Company said the failure could have implications for its other products under development